Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VRT106 + chemotherapy
- Development stage
- Unknown
- Lead developer
- Guangzhou Virotech Pharmaceutical
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
VRT106 + chemotherapy is an experimental combination therapy being evaluated for the treatment of resectable pancreatic cancer. VRT106 is a recombinant oncolytic herpes simplex virus type 1 (oHSV-1) designed to selectively infect and replicate within tumor cells, leading to direct cell lysis and the subsequent release of tumor-associated antigens. This process is intended to stimulate a systemic anti-tumor immune response. When combined with standard-of-care chemotherapy, the regimen aims to provide synergistic cytotoxic effects, potentially reducing tumor volume and improving surgical outcomes or survival in patients with pancreatic adenocarcinoma. The combination is currently under investigation in clinical trials sponsored by Guangdong Provincial People's Hospital.
- Other names
- VRT106 in combination with chemotherapyVRT-106 in combination with chemotherapyVRT 106 in combination with chemotherapyVRT106 plus chemotherapyVRT-106 plus chemotherapyVRT 106 plus chemotherapy
02
Targets
MXRA8 (Matrix remodeling-associated protein 8)DNA
Beyond the preview
Go deeper on VRT106 + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VRT106 + chemotherapy.